Pricing & Reimbursement
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
ICER’s Final NASH Report Urges Step Therapy, Specialist Prescribing, Equitable Access
When the first non-alcoholic steatohepatitis drugs reach market, the health cost watchdog says payers will be justified in setting step-therapy including weight-management efforts, while early prescribing should be by specialists.
Chinese Public Payer Data Show More New Drugs Get Faster Coverage
China’s Basic Medical Insurance Fund spent 7.1 times more on novel drugs in 2022 compared to 2019, according to figures disclosed by the National Healthcare Security Administration. Meanwhile, such drugs need to wait less to be eligible for reimbursement in China.
CMS Official Calls Medicare Price Negotiations An ‘Ongoing Conversation’
The US Centers for Medicare & Medicaid Services’ Vinod Mitta discussed the agency’s latest thinking on the implementation of Medicare drug price negotiations at the Financial Times Pharma Summit.
Stock Watch: Orphan Drug Profitability Under Threat
The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?
Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business
US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira.
FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices
The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.
Regeneron CEO Takes Industry Counterview On FTC News: “I’m Glad They’re Looking Into This”
Leonard Schleifer said it is time for US regulators to review whether certain rebate practices are anti-competitive, while speaking at the Financial Times US Pharma & Biotech Summit.
Big Pharma R&D Chiefs On IRA’s Unintended Casualty, Product Life Cycle Compression
R&D heads of Takeda, Amgen, Lilly and Novartis discuss some of the tectonic forces shaping the biopharma sector and the unintended consequences of the IRA on small molecule innovation. Advances in the neurodegenerative diseases segment amid impressive data from donanemab was another key talking point.
Stock Watch: Queasiness After The Humira Banquet
The second week of first-quarter earnings featured AbbVie’s announcement and a harsh stock price reaction. There were also far-reaching implications behind the results.
ICER’s NASH Panel Shows Some Enthusiasm For Resmetirom, None For OCA
The cost-effectiveness group voted by a slight margin that Madrigal’s non-alcoholic steatohepatitis drug offers benefit above lifestyle changes alone, but decisively that Intercept’s candidate does not.
BioMarin’s $1m Gene Therapy Roctavian Hits Payer Problems In Germany
BioMarin has yet to treat a patient with Roctavian, the first ever hemophilia A gene therapy, eight months after its first approval in Europe, as pricing delays cloud its commercial prospects.
Takeda’s Weber On Digitalizing Pharma In Ongoing Strategic Shift
The entire pharmaceutical industry will transform itself with digital technology while still facing the challenge of financial balance as a part of the healthcare ecosystem, says Takeda's CEO, who shared his views on the firm’s and wider industry's shifting business and R&D strategies at the recent CPHI Japan meeting.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.